These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24884840)

  • 1. Recurrent erysipelas--risk factors and clinical presentation.
    Inghammar M; Rasmussen M; Linder A
    BMC Infect Dis; 2014 May; 14():270. PubMed ID: 24884840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Erysipelas. Retrospective study of 647 patients].
    Zaraa I; Zeglaoui F; Zouari B; Ezzine N; Fazaa B; Kamoun MR
    Tunis Med; 2004 Nov; 82(11):990-5. PubMed ID: 15822466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent erysipelas: 47 cases.
    Leclerc S; Teixeira A; Mahé E; Descamps V; Crickx B; Chosidow O
    Dermatology; 2007; 214(1):52-7. PubMed ID: 17191048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidemiology, clinical features, and evolution of Erysipelas in the Marrakech region (100 cases)].
    Amal S; Houass S; Laissaoui K; Moufid K; Trabelsi M
    Med Mal Infect; 2004 Apr; 34(4):171-6. PubMed ID: 15619888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent erysipelas: risk factors.
    Pavlotsky F; Amrani S; Trau H
    J Dtsch Dermatol Ges; 2004 Feb; 2(2):89-95. PubMed ID: 16279242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erysipelas of the leg: A cross-sectional study of risk factors for recurrence.
    Hali F; Belanouane S; Zarouali Ouariti K; Sodqi M; Chiheb S
    Ann Dermatol Venereol; 2022 Jun; 149(2):119-122. PubMed ID: 34742579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors of recurrent erysipelas in adult Chinese patients: a prospective cohort study.
    Li A; Wang N; Ge L; Xin H; Li W
    BMC Infect Dis; 2021 Jan; 21(1):26. PubMed ID: 33413190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for the prevention of recurrent erysipelas and cellulitis.
    Dalal A; Eskin-Schwartz M; Mimouni D; Ray S; Days W; Hodak E; Leibovici L; Paul M
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD009758. PubMed ID: 28631307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Search of Risk Factors for Recurrent Erysipelas and Cellulitis of the Lower Limb: A Cross-Sectional Study of Epidemiological Characteristics of Patients Hospitalized due to Skin and Soft-Tissue Infections.
    Sapuła M; Krankowska D; Wiercińska-Drapało A
    Interdiscip Perspect Infect Dis; 2020; 2020():1307232. PubMed ID: 32454817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzathine penicillin G once-every-3-week prophylaxis for recurrent erysipelas a retrospective study of 132 patients.
    Rob F; Hercogová J
    J Dermatolog Treat; 2018 Feb; 29(1):39-43. PubMed ID: 28489486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erysipelas, a large retrospective study of aetiology and clinical presentation.
    Bläckberg A; Trell K; Rasmussen M
    BMC Infect Dis; 2015 Sep; 15():402. PubMed ID: 26424182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk factors associated with leg erysipelas (cellulitis) in sub-Saharan Africa: A multicentre case-control study].
    Pitché P; Diatta B; Faye O; Diané BF; Sangaré A; Niamba P; Mandengue C; Kobengue L; Saka B; Diop A; Ly F; Dieng MT; Dicko A; Soumah MM; Cissé M; Kourouma SH; Kouassi YI; Boukari T; Akakpo S; Tchangaï-Walla K
    Ann Dermatol Venereol; 2015 Nov; 142(11):633-8. PubMed ID: 26364000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Erysipelas in the young population of a military hospital].
    Mahé E; Toussaint P; Lamarque D; Boutchnei S; Guiguen Y
    Ann Dermatol Venereol; 1999; 126(8-9):593-9. PubMed ID: 10530346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiological data and comorbidities of 428 patients hospitalized with erysipelas.
    Pereira de Godoy JM; Galacini Massari P; Yoshino Rosinha M; Marinelli Brandão R; Foroni Casas AL
    Angiology; 2010 Jul; 61(5):492-4. PubMed ID: 20147345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and epidemiological assessment of patients hospitalized for primary and recurrent erysipelas.
    Kozłowska D; Myśliwiec H; Kiluk P; Baran A; Milewska AJ; Flisiak I
    Przegl Epidemiol; 2016; 70(4):575-584. PubMed ID: 28221013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of reduction operation with genital lymphedema on the frequency of erysipelas and the quality of life.
    Zvonik M; Földi E; Felmerer G
    Lymphology; 2011 Sep; 44(3):121-30. PubMed ID: 22165582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with acute and recurrent erysipelas in a young population: a retrospective of 147 cases.
    Chamli A; Jaber K; Ben Lagha I; Ben Slimane M; Rabhi F; Doss N; Dhaoui MR
    Tunis Med; 2021 Aout; 99(8):886-889. PubMed ID: 35261016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erysipelas as a sign of subclinical primary lymphoedema: a prospective quantitative scintigraphic study of 40 patients with unilateral erysipelas of the leg.
    Damstra RJ; van Steensel MA; Boomsma JH; Nelemans P; Veraart JC
    Br J Dermatol; 2008 Jun; 158(6):1210-5. PubMed ID: 18363756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bacterial dermohypodermitis and necrotizing fascitis: 104-case series from Togo].
    Saka B; Kombaté K; Mouhari-Toure A; Akakpo S; Boukari T; Pitché P; Tchangaï-Walla K
    Med Trop (Mars); 2011 Apr; 71(2):162-4. PubMed ID: 21695874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Erysipelas: epidemiological, clinical and therapeutic data (111 cases)].
    Crickx B; Chevron F; Sigal-Nahum M; Bilet S; Faucher F; Picard C; Lazareth I; Belaich S
    Ann Dermatol Venereol; 1991; 118(1):11-6. PubMed ID: 2018300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.